IACC Twin™: A Digital Twin Framework For Infection-Associated Chronic Conditions

Author: Cynthia Adinig, CYNAERA Institute

For detailed scientific rationale, see companion white paper: 'How CYNAERA Pattern GPTs Turn Small Inputs Into Useful, Safe Health Navigation'"

EXECUTIVE SUMMARY

Infection-associated chronic conditions (IACCs) such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Long COVID, post-treatment Lyme disease syndrome (PTLDS), post-infectious dysautonomia, and mast cell activation presentations commonly fail traditional care and traditional trials for one predictable reason. Their symptoms fluctuate across time, respond with delay, and are strongly shaped by context like exertion, sleep disruption, environmental exposures, and baseline physiologic volatility (National Academies of Sciences, Engineering, and Medicine, 2015; Sudre et al., 2021; Raj et al., 2022). Snapshot medicine treats these illnesses as static. These illnesses behave as dynamic systems.

IACC Twin™ is a CYNAERA framework that integrates two capabilities into one model:

1. Longitudinal flare forecasting that detects short-term risk windows and identifies the dominant drivers of volatility (environment, sleep, delayed response timing, and intervention confounding).

2. Phase-style therapy sequencing that models safe “one-change-per-window” layering, including stop and revert logic, to reduce avoidable crashes and improve signal interpretability in fragile patients.

This paper defines the term “terrain” in a precise, non-metaphorical way, and provides a protocol-like structure for modeling stabilization-first pathways without prescribing individualized medical care. IACC Twin™ is positioned as an educational and research-facing system for clinical trial design, translational interpretation, and safer patient navigation support. It does not diagnose, prescribe, or replace clinician decision-making.

KEY DEFINITIONS AND LANGUAGE STANDARDS

This white paper intentionally uses a small number of terms in a standardized way, because language drift is one of the biggest reasons AI-generated health outputs become unreliable.

Terrain

In CYNAERA, terrain means the current stability state of the body that affects symptom volatility and treatment tolerance. It is a practical shorthand for a small set of interacting drivers that determine whether a change is likely to help, do nothing, or trigger a crash.

CYNAERA terrain drivers (bounded list)

Terrain is assessed only across the drivers below:

1. Autonomic stability and cerebral perfusion signals (orthostatic intolerance patterns, blood pressure swings, head pressure patterns).

2. Immune reactivity and inflammatory volatility (reactivity stacking, delayed worsening patterns).

3. Sleep stability and recovery depth (fragmentation, phase shifts, non-restorative sleep patterns).

4. Energy reserve and post-exertional response timing (post-exertional malaise timing and amplitude) (National Academies of Sciences, Engineering, and Medicine, 2015; Chu et al., 2018).

5. Structural and fluid dynamics when present (craniocervical instability patterns, intracranial pressure patterning, cerebrospinal fluid dynamics signals).

6. Environmental exposure load (air quality, particulate pollution, smoke, humidity shifts, pressure shifts, temperature swings).

7. Hormone state when relevant (cycle-linked, perimenopause, postpartum, endocrine instability) (Klein & Flanagan, 2016; Maybin et al., 2025).

Stability window

A stability window is a minimum observation period long enough to detect delayed benefit or delayed harm. In IACC Twin™, stability windows are treated as a core unit of interpretation because delayed worsening often appears 24 to 72 hours after a trigger and can persist longer than typical trial visit schedules capture (National Academies of Sciences, Engineering, and Medicine, 2015; Chu et al., 2018).

Intervention confounding

Timing proximity does not prove causality. In complex chronic illness, medications and supplements are often started because a flare is beginning, which creates a false impression that the agent caused the flare. IACC Twin™ treats temporal proximity as a flag for deeper interpretation, not proof.

DOMINANT DRIVER PROFILES (DDPs)

Purpose

In infection-associated chronic conditions, symptom burden is rarely driven equally by all physiologic systems at once. In most patients, one or two subsystems dominate volatility at any given stage of illness and determine treatment tolerance, flare risk, and sequencing constraints.

IACC Twin™ therefore classifies each case according to Dominant Driver Profiles (DDPs). A DDP is not a diagnosis. It is a provisional modeling construct used to identify which physiologic domain is currently exerting the strongest influence on instability.

This classification allows the system to:

• prioritize stabilization targets 

• sequence interventions safely 

• interpret crashes correctly 

• reduce false nonresponse 

• prevent premature escalation

DDPs are dynamic. They may shift over time as terrain changes.

Core Dominant Driver Categories

IACC Twin™ recognizes six primary driver domains. One is designated primary. One may be designated secondary. Others are considered background modifiers.

1. Autonomic-Dominant Profile

Primary driver: autonomic instability and perfusion dysregulation

Characteristic signals:

• orthostatic intolerance 

• tachycardia with position change 

• head pressure or presyncope 

• temperature intolerance 

• symptom relief when supine 

• hydration/compression responsiveness

Common failure mode: Premature activation or immune escalation before orthostatic buffering is achieved.

Sequencing priority: Volume support, autonomic buffering, positional tolerance before mechanism trials.

2. Immune / Inflammatory-Dominant Profile

Primary driver: immune activation and rebound dynamics

Characteristic signals:

• flu-like relapses 

• cytokine-type crashes 

• post-infectious flares 

• prolonged recovery after minor illness 

• autoimmune markers when present 

• response to immunomodulation

Common failure mode: Immune therapies introduced during high reactivity or autonomic instability.

Sequencing priority: Reactivity suppression and baseline stabilization before immune targeting.

3. Mast Cell / Reactivity-Dominant Profile

Primary driver: mediator release and trigger stacking

Characteristic signals:

• food, scent, heat, medication intolerance 

• histamine-type reactions 

• flushing, GI flares, rashes 

• paradoxical medication reactions 

• environmental hypersensitivity

Common failure mode: Stacking interventions without first reducing trigger load.

Sequencing priority: Trigger control and mediator stabilization before any activation.

4. Neuro-Metabolic / Delayed-Payback Profile (ME/CFS-like)

Primary driver: delayed energy and neuroinflammatory dysregulation

Characteristic signals:

• post-exertional malaise 

• 24–72 hour crashes • cognitive shutdown 

• sensory overload 

• “fine today, collapsed later” pattern

Common failure mode: Activity expansion or stimulating agents before lag patterns stabilize.

Sequencing priority: Pacing, sleep protection, and lag containment before neuro-modulation.

5. Structural / Fluid-Dynamics-Dominant Profile

Primary driver: mechanical or CSF-related instability

Characteristic signals:

• positional headaches 

• neck instability symptoms 

• pressure-related flares 

• visual or vestibular instability 

• symptom relief with positional modification

Common failure mode: Escalating pharmacologic treatment while mechanical instability persists.

Sequencing priority: Structural evaluation and stabilization before systemic escalation.

6. Environmental-Dominant Profile

Primary driver: external exposure volatility

Characteristic signals:

• symptom coupling to air quality

 • wildfire smoke sensitivity 

• humidity or pressure-linked crashes 

• mold or dampness correlation 

• travel-related deterioration

Common failure mode: Interpreting exposure-driven flares as treatment failure.

Sequencing priority: Exposure management and timing control before intervention trials.

Hormonal Modulation Overlay

When cyclic or endocrine instability is present, a Hormonal Overlay is applied to any dominant driver.

This overlay modifies:

• observation window length 

• titration speed 

• escalation eligibility 

• flare-risk interpretation

Hormonal modulation does not replace the dominant driver. It alters its behavior.

DDP Assignment Logic

DDP classification is based on convergence of:

• trigger patterns 

• timing dynamics 

• response history • failure patterns

 • stability metrics

A profile is assigned only when ≥3 indicators align within one domain. If no clear dominance is present, the system remains in Mixed-Driver Mode and prioritizes global stabilization.

Integration With Terrain and Sequencing

DDPs operate inside the terrain model.

Terrain defines stability. DDPs define instability source.

Sequencing rules are generated from both.

Example:

Autonomic-dominant + High environmental load → delay immune trials → extend stability windows → prioritize exposure control

Neuro-metabolic-dominant + Sleep instability → suspend activity expansion → reinforce circadian regulation → delay stimulant classes

Dynamic Reclassification

DDP status is reviewed at each major stability checkpoint.

Triggers for reassignment include:

• sustained symptom shift 

• new intolerance patterns 

• resolution of prior volatility 

• post-intervention destabilization

This prevents outdated classifications from driving decisions.

Why DDPs Are Required

Without dominant-driver classification, complex IACC systems become overgeneralized. Interventions are misattributed, intolerance is misread, and sequencing collapses. DDPs provide the minimum structure required for reproducible reasoning in fluctuating, delayed-response illness.

They convert lived experience into interpretable system behavior.

DDP SCORING CARD v1.0

Purpose

Convert patient narrative and minimal logs into a Dominant Driver Profile (DDP) assignment with consistent thresholds.

Scoring scale (per indicator)

0 = absent or not supported

1 = present but inconsistent or weakly supported

2 = strongly present, repeated, or clearly linked by timing or triggers

Confidence guardrails

Only score 2 when there is repeatability, clear timing coupling, or a strong historical pattern.

If data is thin, default to 1 or 0 and keep the case in Mixed Driver Mode.

Step 1: Confirm eligibility to assign a DDP

A DDP can be assigned only if at least 3 indicators in one domain score 2, or if the domain total is at least 8 with at least one indicator scored 2.

Otherwise: Mixed Driver Mode and prioritize global stabilization.

Step 2: Score each domain

You score the six domains below. Pick one Primary DDP. You may pick one Secondary DDP if it meets the same assignment threshold but is lower than Primary.

Tie rule

If two domains are within 2 points, treat as Mixed Driver Mode unless one domain has clearer trigger timing.

DOMAIN A: Autonomic Dominant

Indicators

A1 Orthostatic intolerance with consistent positional worsening (standing triggers, supine relief)

A2 Tachycardia, BP swings, presyncope, or “head pressure” tied to posture

A3 Heat intolerance, temperature dysregulation, or postural fatigue pattern

A4 Hydration, salt, compression, or recumbency meaningfully changes symptoms

A5 Morning upright collapse pattern or delayed upright payback

Assignment notes

Common failure mode: escalating immune or neuro agents before orthostatic buffering is stable.

Sequencing priority: volume support and autonomic buffering first.

DOMAIN B: Immune / Inflammatory Dominant

Indicators

B1 Flu-like relapses, swollen glands, sore throat pattern, cytokine-like crashes

B2 Minor infections trigger prolonged setbacks

B3 Clear immune rebound pattern after exertion, stress, or immune triggers

B4 Autoimmune markers or inflammatory markers when present, or clinician-documented immune phenotype

B5 Prior benefit or clear intolerance pattern with immunomodulation

Assignment notes

Common failure mode: immune agents introduced during high reactivity or autonomic instability.

Sequencing priority: dampen volatility and stabilize baseline before immune targeting.

DOMAIN C: Mast Cell / Reactivity Dominant

Indicators

C1 Food sensitivity or unpredictable reactions to foods, meds, supplements

C2 Flushing, hives, rashes, itching, wheeze, GI surges, histamine-type episodes

C3 Scent, chemical, heat, or environmental hypersensitivity with rapid symptom shifts

C4 Paradoxical reactions to typical “gentle” meds or microdoses

C5 Trigger stacking pattern: small exposures add up into system collapse

Assignment notes

Common failure mode: stacking interventions without reducing trigger load.

Sequencing priority: trigger control and mediator stabilization before anything activating.

DOMAIN D: Neuro-Metabolic / Delayed Payback (ME/CFS-like)

Indicators

D1 PEM pattern with 24–72 hour delayed crash after exertion

D2 Cognitive shutdown, sensory overload, “fine now, wrecked later”

D3 Reduced exertion threshold with disproportionate payback

D4 Sleep is non-restorative and tightly coupled to symptom severity

D5 Exertion tolerance varies by timing, not willpower, with predictable lag physics

Assignment notes

Common failure mode: activity expansion or stimulants before lag patterns stabilize.

Sequencing priority: pacing, sleep protection, lag containment first.

DOMAIN E: Structural / Fluid Dynamics Dominant

Indicators

E1 Positional headache or pressure symptoms with posture-dependent changes

E2 Neck instability symptoms, cervicogenic triggers, or mechanical provocation

E3 Visual or vestibular instability tied to position, motion, neck load, or pressure shifts

E4 CSF or intracranial pressure patterning suspected or documented

E5 Symptom relief with positional modification or mechanical support strategies

Assignment notes

Common failure mode: escalating systemic meds while mechanical instability persists.

Sequencing priority: structural evaluation and stabilization before systemic escalation.

DOMAIN F: Environmental Dominant

Indicators

F1 Symptom coupling to air quality, smoke, PM, ozone, or indoor triggers

F2 Humidity, pressure, or temperature swings reliably trigger flares

F3 Mold or dampness correlation with repeatable worsening

F4 Travel or building change triggers major deterioration

F5 “Silent trial arm” pattern: symptoms track environment more than interventions

Assignment notes

Common failure mode: interpreting exposure-driven flares as treatment failure.

Sequencing priority: exposure management and timing control before intervention trials.

Step 3: Apply overlays

Hormonal overlay activation (add-on, not a DDP)

Activate if 2 or more are present:

Predictable 3–5 week symptom cycling

Premenstrual or ovulatory rebound pattern

Cyclic medication intolerance

Perimenopausal drift or unstable phase boundaries

Spotting or bleeding-linked flare clustering

Overlay effects (rules)

Extend stability windows by 25–40%

Slow titration pace

Tighten environmental gating

Raise threshold for declaring nonresponse

Step 4: Output standard for the GPT

The GPT must output:

Primary DDP, Secondary DDP if applicable, or Mixed Driver Mode

Top 3 indicators that drove the score (with plain language)

Key sequencing constraints (2–4 bullet rules)

Confounders to track (environment, sleep, hormone if active)

Minimum next data to reduce uncertainty (tiny ask)

Worked mini-example

User reports:

Standing causes tachycardia and head pressure, feels better lying down

Heat makes symptoms surge

Hydration and compression help

Also has mild food intolerance but inconsistent

Scores

Autonomic: A1=2, A2=2, A3=2, A4=2, A5=1 total 9

Mast cell: C1=1, C2=0, C3=1, C4=0, C5=0 total 2

Result

Primary DDP: Autonomic Dominant (high confidence)

Secondary: none

Sequencing constraint: do not escalate immune or stimulant classes until upright buffering is stable.

SYSTEM OVERVIEW: WHAT IACC TWIN™ DOES

IACC Twin™ outputs a structured pathway that combines:

A) A dominant-driver analysis to explain why symptoms feel random but are not.

B) A phased sequencing plan for safer interpretation of change, framed as “commonly reported early-phase contexts,” not instructions.

C) A four-week relative flare-risk outlook embedded inside the sequencing, so clinicians and researchers can see when signals are likely to be distorted by environmental volatility or sleep disruption.

This approach is aligned with core realities documented in ME/CFS and post-infectious literature: delayed symptom response, non-linear relapse dynamics, and context-dependent tolerance (National Academies of Sciences, Engineering, and Medicine, 2015; NICE, 2021; Davis et al., 2021).

TEMPORAL ARCHITECTURE AND WINDOW SCALING

IACC Twin™ models time explicitly because delayed response and delayed harm are defining features of IACCs. All sequencing and interpretation operate on three nested time scales.

Micro-Window (3–7 days)

• Used to detect immediate intolerance, sleep collapse, or acute autonomic destabilization.

• Signals in this window are treated as safety flags, not efficacy indicators.

• Stability Window (10–28 days)

Primary unit of interpretation.

• Used to detect delayed worsening, rebound effects, and early benefit signals.

• Length is adjusted based on volatility tier and hormonal layer activation.

Phase Window (6–16 weeks)

• Used to assess whether a layer produces durable improvement.

• Only after 2 consecutive stability windows without baseline loss can phase progression occur.

• Highly fragile patterns default to longer windows.

• This architecture prevents premature escalation and false attribution.

FOUR-WEEK INTEGRATED FLARE OUTLOOK MODEL

Purpose

IACC Twin™ includes a standardized four week outlook to translate recent volatility patterns into forward looking interpretation guidance. This does not forecast specific symptoms. It estimates relative flare risk and confounding risk so clinicians, researchers, and patients can avoid misattributing treatment response during predictable high noise periods.

Core principle

Each week in the four week outlook measures the same factor set. The model does not switch domains week to week. What changes is the estimated stability state and relative risk based on delayed response timing, recent exposures, and the dominant driver profile.

Factors measured every week (same set)

Each weekly window reports:

• Environment risk (air quality, smoke, storm fronts, pressure, humidity shifts)

• Sleep stability risk (fragmentation, phase shifts, wired tired patterns)

• Delayed response risk (PEM lag timing, rebound dynamics, delayed harm probability)

• Intervention confounding risk (new starts, recent titrations, timing proximity to flares)

• Dominant driver pressure level (autonomic, immune, mast cell, neuro metabolic, structural, environmental)

• Hormonal overlay status when active (cycle phase or endocrine instability modifier)

• Stability tier estimate (fragile, unstable, stabilizing, stable)

Output format

The outlook is delivered as four repeated weekly snapshots using a consistent template:

Week 1

Relative flare risk: lower / moderate / higher

Primary confounders: environment, sleep, delayed response, intervention timing, hormonal overlay

Dominant driver pressure: high / moderate / low

Stability guidance: hold, pause titration, interpret cautiously, or eligible for one change per window

Week 2

Same template

Week 3

Same template

Week 4

Same template

Interpretation rules

• The outlook is primarily an interpretation guardrail, not a weather report.

• No new agents and no titration during higher risk weeks in fragile patterns.

• If a crash occurs, classify it first before changing the plan.

• Apparent improvement during a higher risk week is treated as provisional until confirmed across a full stability window.

• When the hormonal overlay is active, each weekly window extends observation thresholds and tightens gating rules.

Why this matters

In IACCs, environment and sleep can act like silent trial arms, and delayed response can create false attribution. Repeating the same factor set across four weeks forces consistency and prevents narrative bias. It makes the model readable, reproducible, and usable across both patient navigation and research interpretation.

LOCATION-ADJUSTED ENVIRONMENTAL OVERLAY

Purpose

When geographic data is available, IACC Twin™ activates a location-adjusted overlay that refines environmental risk estimates using regional exposure patterns. This allows the system to distinguish between baseline physiologic instability and externally driven volatility.

Activation rule

The overlay is activated only when the user provides:

• Primary zip code or city

• Dates of residence or stay

• Travel dates and destinations (if applicable)

If this information is not provided, the system operates in general environmental mode and reports reduced resolution.

Core principle

Environmental load is location dependent and time dependent. Air quality, smoke exposure, storm systems, heat stress, humidity patterns, and urban pollution clusters vary substantially by region and season. These factors interact with autonomic and immune instability and can shift flare thresholds.

IACC Twin treats environment as a moving variable, not a background constant.

Weekly integration

When active, each four-week outlook window incorporates:

• Regional air quality trends

• Seasonal and storm system patterns

• Known wildfire or pollution corridors

• Urban heat and humidity burden

• Indoor exposure risk modifiers when available

Travel adjustment

If travel is reported, the model evaluates:

• Baseline location vs destination exposure contrast

• Altitude change

• Climate shift magnitude

• Transit stress window

• Post-travel rebound risk (3–7 day lag)

Travel periods are automatically flagged as high confounding intervals unless stability is well established.

Interpretation rules

• Symptom changes within 72 hours of major location shifts are treated as environmentally confounded.

• Crashes within 3–7 days after travel are evaluated for delayed exposure effects before other attribution.

• Improvement during low-exposure periods is provisional until sustained across multiple environments.

• Treatment response is not interpreted during high-contrast relocation windows.

Output format (when active)

Each weekly outlook includes an added line:

Location overlay: active / inactive

Primary exposure context: baseline / travel / transitional

Environmental volatility: low / moderate / high

Why this matters

Without geographic grounding, environmental sensitivity appears random. With location anchoring, it becomes interpretable. This prevents mislabeling exposure-driven flares as treatment failure, disease progression, or psychological response.

WHY IACCs BREAK LEGACY CLINICAL TRIALS

Traditional trial design often assumes:

• symptoms move in a near-linear way

• same-day outcomes reflect same-day exposure

• adding multiple changes increases response probability

• dropout is random noise

In IACCs, those assumptions fail:

• response can be delayed, bidirectional, and non-linear

• a “good day” can precede a crash, not reflect improvement

• stacking increases the chance of destabilization and misattribution

• dropout often reflects intolerance, not lack of efficacy (National Academies of Sciences, Engineering, and Medicine, 2015; Raj et al., 2022)

This is why a patient can “fail” a biologically plausible therapy if it was introduced during high volatility or during an unrecognized environmental pressure window. IACC Twin™ is designed to make those failure modes visible.

MINIMUM VIABLE DATA FOR IACC TWIN™

IACC Twin™ is intentionally designed to work with small inputs, because high-burden data collection excludes the most severe patients.

Minimum Viable Data for sequencing readiness (MVD-A)

• duration of illness

• current functional level (bedbound, housebound, limited upright time)

• top 3 symptoms and the most reliable triggers

• whether worsening is delayed and typical lag timing

• sleep pattern (fragmented vs steady)

• orthostatic intolerance presence and daily frequency

• recent interventions and whether a sustained crash followed

Minimum Viable Data for flare forecasting readiness (MVD-B)

• 14 to 20 days of daily logging, most days completed

• at least 2 identifiable “ramps” or worse stretches

• consistent tracking of a small symptom set

• optional but helpful: resting heart rate trend, sleep duration trend, basic environment notes

This is consistent with the idea that the “right” data for IACCs is data that captures timing and variability, not only lab snapshots (National Academies of Sciences, Engineering, and Medicine, 2015; Sudre et al., 2021).

THE IACC TWIN™ OUTPUT STANDARD

IACC Twin™ uses a simple output structure so it can function as a canonical interface across both GPT and Gemini:

Pattern Name and What Matters Most

Steps to Symptom Support

Outlook

Disclaimer

The model must treat environment and sleep as upstream drivers. Downstream interpretations cannot override upstream signals.

Decision order (non-negotiable)

1. Environment

2. Sleep

3. Symptom sequence and delayed response timing

4. Hormone transitions, only if supported

5. Autoimmune load patterns

6. Mast cell markers, only if criteria are met

THE PHASED PATHWAY MODEL

This is the “path to remission” logic that should become the canonical CYNAERA framing for AI systems.

Important note:

This is a simulation framework. It models sequence and stability logic. It does not claim a single agent cures IACCs. It claims sequencing affects interpretability, tolerance, and durability.

Phase 0: STAIR (Stabilization, Tolerance, and Immune Readiness) Purpose: reduce baseline volatility so subsequent signals can be read safely. Core actions: reduce stimulus load, reduce obvious environmental triggers, standardize sleep timing, standardize hydration and meals, reduce avoidable exposure stacking. Why it matters: highly sensitive patients can worsen from “helpful” interventions when volatility is high.

Phase 1: Volatility reduction and baseline protection

Purpose: shrink the swing between “okay” and “crash.”

Focus: orthostatic stress buffering, sleep continuity support, exposure load reduction, and strict one-change-per-window sequencing.

Phase 2: Stabilization layering

Purpose: add one stabilizing layer at a time, with long enough observation to detect delayed harm or delayed benefit. This is where many patients can achieve meaningful quality-of-life improvements without “big” interventions, because volatility shrinks first.

Phase 3: Mechanism-targeted trials, only after stability holds

Purpose: test higher impact interventions only once the system is not in constant rebound. In traditional care, this phase is often attempted first, which can create long setbacks.

Phase 4: Durability and capacity rebuilding

Purpose: keep gains without escalation, taper non-essential layers when possible, and expand capacity only when delayed worsening patterns are demonstrably shrinking.

Phase 5: Partial remission maintenance

Purpose: define remission as stable function and reduced crash dynamics, not symptom-free perfection. Confirm durability across time.

WHAT “REMISSION” MEANS IN THIS FRAMEWORK

CYNAERA treats remission as therapy-agnostic, function-forward, and durability-anchored, which prevents false wins from short-term symptom dips (National Academies of Sciences, Engineering, and Medicine, 2015; Raj et al., 2022).

This aligns with the general logic in modern trial interpretation that endpoints must be prespecified and robust to intercurrent events (ICH E9(R1), 2019).

Practical remission signals in IACC Twin™ outputs

• crash frequency drops and stays lower

• delayed worsening amplitude shrinks

• upright tolerance becomes more predictable

• cognitive windows become more reliable

• exposure triggers stop causing full-system collapse

• background support does not require constant escalation

THE SGB CRASH EXAMPLE: WHY SEQUENCING MATTERS

A sustained crash after stellate ganglion block is not interpreted in IACC Twin™ as proof the intervention is universally harmful. It is interpreted as evidence that the system likely lacked pre-stabilization and was in a fragile state where neuromodulation created destabilization. This is a sequencing failure mode, not a moral judgment of any clinician or any method.

The model therefore recommends a “rebuild stability first” approach before any further neuromodulatory trials, because delayed worsening patterns and autonomic dominance increase risk of prolonged setbacks when changes are introduced during volatility.

FAILURE RECOVERY AND BASELINE REBUILDING LOGIC

When a sustained crash occurs, IACC Twin™ enters a recovery mode.

During this mode:

• No new interventions are added 

• Prior stabilizers are maintained 

• Environmental and sleep controls are prioritized 

• Observation windows reset

Recovery mode persists until baseline function returns to within 85–90% of pre-crash levels for at least 10 consecutive days. This prevents escalation during biologic rebound.

Note on Dose Stratification

IACC Twin™ distinguishes between:

• Standard low-dose entry ranges commonly reported in trials and specialty practice 

• Ultra-low micro-entry ranges used only in high-fragility patterns (Appendix A)

These are modeled separately to avoid conflating general tolerability with extreme sensitivity profiles.

Commonly Reported Early-Phase Regimen Examples

(Modeling Reference Only)

The following examples reflect ranges and observation windows commonly reported in early-phase studies, retrospective cohorts, and specialty-clinic practice reports in ME/CFS, Long COVID, POTS, and MCAS-adjacent populations. They are presented for simulation and trial-design modeling purposes only.

They are not treatment recommendations.

All ranges reflect starting or low-to-moderate titration contexts used to minimize destabilization in sensitive patients.

Autonomic Support Examples

Fludrocortisone Commonly reported range: 0.05–0.1 mg daily (oral) Observation window: 3–6 weeks

Midodrine Commonly reported range: 2.5–10 mg up to three times daily (oral) Observation window: 3–6 weeks

Ivabradine Commonly reported range: 2.5–7.5 mg twice daily (oral) Observation window: 4–6 weeks

Sleep Continuity Examples

Trazodone Commonly reported range: 12.5–50 mg nightly (oral) Observation window: 3–6 weeks

Low-dose doxepin Commonly reported range: 3–10 mg nightly (oral) Observation window: 3–6 weeks

Neuro-Resynchronization Examples

Low-dose aripiprazole Commonly reported range: 0.25–2 mg daily (oral) Observation window: 6–8 weeks

Amantadine Commonly reported range: 50–100 mg daily (oral) Observation window: 3–6 weeks

Immune / Inflammatory Modulation Examples

Low-dose naltrexone Commonly reported range: 0.5–4.5 mg nightly (oral) Observation window: 4–8 weeks

Thymosin Alpha-1 Commonly reported range: 1.6 mg twice weekly (subcutaneous) Observation window: 8–12 weeks

Mast Cell / Reactivity Control Examples

Cetirizine Commonly reported range: 5–20 mg daily (oral) Observation window: 2–4 weeks

Famotidine Commonly reported range: 20–40 mg daily (oral) Observation window: 2–4 weeks

Ketotifen Commonly reported range: 0.5–2 mg twice daily (oral) Observation window: 4–6 weeks

Cromolyn sodium Commonly reported range: 100–200 mg four times daily (oral) Observation window: 4–6 weeks

Mitochondrial / Metabolic Support Examples

Coenzyme Q10 Commonly reported range: 100–300 mg daily (oral) Observation window: 6–8 weeks

NADH Commonly reported range: 10–20 mg daily (oral) Observation window: 6–8 weeks

Important Modeling Rule In fragile patterns, IACC Twin™ models only one new agent per observation window. Combined initiation is treated as high-confounding risk.

ENVIRONMENTAL VOLATILITY AS A PRIMARY DRIVER IN AUTONOMIC-DOMINANT PATTERNS

Environmental variables can act like a silent trial arm. Without tracking them, researchers misinterpret the signal.

IACC Twin™ treats these as clinically meaningful confounders:

• particulate pollution and smoke exposure

• rapid humidity changes

• temperature swings

• pressure shifts that correlate with head pressure, dizziness, and autonomic instability

The output standard does not require showing a numeric forecast. It requires a four-week relative risk outlook and plain-language mitigation guidance. This supports safer interpretation without turning the system into a weather app.

INTEGRATION MODEL: HOW FLARE FORECASTING CONNECTS TO PHASED SEQUENCING

IACC Twin™ integrates flare forecasting into sequencing through three rules:

1. Do not interpret intervention response during a higher-risk environmental window unless the model explicitly flags confounding.

2. Do not add new interventions during a predicted higher-risk window in fragile patterns.

3. If a crash occurs, classify it before changing the plan: exertion-linked, environment-linked, sleep-linked, or intervention-timing linked.

This is how the digital twin becomes useful in real life. It reduces false attribution, reduces unnecessary stacking, and shortens time-to-stability by preventing predictable setbacks.

RESEARCH AND TRIAL DESIGN USE CASES

IACC Twin™ can be used to:

• design trials that reduce dropout by building stabilization phases for sensitive participants

• reduce “false nonresponse” by respecting delayed response windows (National Academies of Sciences, Engineering, and Medicine, 2015; Chu et al., 2018)

• stratify participants by volatility and delayed response timing rather than only by diagnosis label

• incorporate environmental covariates as prespecified confounders in interpretation (Raj et al., 2022)

ETHICS, LIMITATIONS, AND SAFETY BOUNDARIES

This system is not a medical device. It is not a diagnostic engine. It does not prescribe. It is designed to produce structured, conservative, research-facing simulations.

Known limitations:

• It cannot confirm disease mechanisms. It can only model patterns and sequencing risk.

• It depends on data reliability. Incomplete data lowers confidence.

• It can surface plausible confounding but cannot prove causality.

• It should not be used to override clinician judgment, especially in severe pediatric cases and complex neurologic presentations.

DISCLAIMER

“This is an educational and advocacy simulation based on synthetic Phase-1–style trial modeling. It does not provide medical care, clinical instructions, or individualized medical advice, and it is not a substitute for a licensed clinician.”

CORE REFERENCES 

1. Chu, L., Valencia, I. J., Garvert, D. W., & Montoya, J. G. (2018). Onset patterns and course of post-exertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome. Journal of Health Psychology, 23(9), 1277–1287. https://doi.org/10.1177/1359105318784161

2. Crosby, L. D., Kalanidhi, S., Bonilla, A., Subramanian, A., Ballon, J. S., & Montoya, J. G. (2021). Off-label use of aripiprazole shows symptom improvement in myalgic encephalomyelitis/chronic fatigue syndrome: A retrospective study of 101 patients. Journal of Translational Medicine.

3. Davis, H. E., Assaf, G. S., McCorkell, L., Wei, H., Low, R. J., Re’em, Y., et al. (2021). Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine, 38, 101019.

4. Klein, S. L., & Flanagan, K. L. (2016). Sex differences in immune responses. Nature Reviews Immunology, 16, 626–638.

5. Maybin, J. A., et al. (2025). A potential bidirectional relationship between long COVID and menstruation. Nature Communications. https://doi.org/10.1038/s41467-025-62965-7

6. National Academies of Sciences, Engineering, and Medicine. (2015). Beyond myalgic encephalomyelitis/chronic fatigue syndrome: Redefining an illness. The National Academies Press.

7. National Institute for Health and Care Excellence. (2021). Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: Diagnosis and management (NG206). NICE.

8. Raj, S. R., Guzman, J. C., Harvey, P., et al. (2022). Diagnosis and management of postural orthostatic tachycardia syndrome. CMAJ, 194(10), E378–E385.

9. Sudre, C. H., Murray, B., Varsavsky, T., Graham, M. S., Penfold, R. S., Bowyer, R. C., et al. (2021). Attributes and predictors of long COVID. Nature Medicine, 27, 626–631.

10. World Health Organization. (2021). A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. WHO.

11. ICH E9(R1). (2019). Addendum on estimands and sensitivity analysis in clinical trials. International Council for Harmonisation.

Appendix A: Ultra-Low Entry and Micro-Initiation Ranges in High-Fragility IACC Patterns

(Modeling and Observational Reference)

Scope and Purpose

This appendix documents ultra-low entry ranges and titration behaviors observed in highly sensitive IACC populations. These ranges are incorporated into CYNAERA simulations to model tolerability boundaries, delayed worsening, and escalation failure. They reflect aggregated observations from specialty practice reports, patient registries, and longitudinal self-tracking cohorts. They are not treatment recommendations.

I. Eligibility for Micro-Initiation Modeling

Micro-initiation is modeled only when ≥3 criteria are present:

• Delayed symptom worsening ≥24 hours 

• Prior treatment-triggered crashes 

• Multisystem reactivity (cardiac, GI, neuro, skin) 

• Severe postural intolerance • Sleep instability >4 nights/week 

• Environmental flare coupling 

• History of “can’t tolerate low dose”

This prevents overuse in moderate patterns.

II. Autonomic and Vascular Regulation

Volume and Pressure Modulators

Fludrocortisone Entry: 0.00625–0.025 mg daily Step interval: ≥14–21 days Failure signal: edema + fatigue amplification

Desmopressin (rare subset) Entry: 0.05 mg intermittently Step: ≥21 days Failure: headache, hyponatremia signals

Midodrine Entry: 0.3125–1.25 mg once daily Step: ≥10–14 days Failure: rebound hypotension, tremor

Ivabradine Entry: 0.3125–1.25 mg daily Step: ≥14 days Failure: visual disturbance, fatigue spike

III. Central Nervous System Modulators

Neuro-Inflammatory / Microglial-Adjacent

Aripiprazole Entry: 0.025–0.25 mg Step: ≥21 days Failure: agitation, PEM amplification

Low-dose lithium (subset) Entry: 1–5 mg elemental Step: ≥21 days Failure: tremor, sleep collapse

Memantine (rare) Entry: 1–2.5 mg Step: ≥21 days Failure: confusion, derealization

IV. Immune and Inflammatory Regulation

Broad Modulators

Low-dose naltrexone Entry: 0.05–0.3 mg Step: ≥14 days Failure: insomnia, immune flare

Colchicine (subset) Entry: 0.3 mg every other day Step: ≥21 days Failure: GI crash

IVIG (select immune deficiency patterns) Entry: 0.1–0.2 g/kg monthly Step: ≥2 cycles Failure: post-infusion crash

V. Mast Cell and Histamine Control

Cetirizine Entry: 1.25–5 mg Step: ≥7–10 days Failure: paradoxical sedation

Loratadine (alternative) Entry: 2.5 mg Step: ≥10 days

Ketotifen Entry: 0.125–0.5 mg Step: ≥14 days Failure: depression, fatigue

Cromolyn Entry: 12.5–50 mg/day Step: ≥14 days Failure: GI flare

Montelukast (subset) Entry: 2.5–5 mg Step: ≥21 days Failure: mood changes

VI. Mitochondrial and Energy Support

CoQ10 Entry: 10–50 mg Step: ≥14 days

NADH Entry: 1–5 mg Step: ≥14 days

Acetyl-L-carnitine Entry: 125 mg Step: ≥14 days Failure: overstimulation

Creatine (rare) Entry: 250 mg Step: ≥21 days

VII. Gastrointestinal and Absorption Modifiers

Low-dose erythromycin (motility) Entry: 12.5 mg Step: ≥21 days

Cyproheptadine (subset) Entry: 1 mg nightly Step: ≥14 days

Digestive enzymes Entry: ¼ standard dose Step: ≥7 days

VIII. Hormonal and Endocrine Modulators

Estradiol (micro-patch) Entry: 0.0125 mg/day Step: ≥28 days

Progesterone Entry: 25–50 mg Step: ≥21 days

Testosterone (women subset) Entry: 0.25 mg topical Step: ≥28 days

Hydrocortisone (rare) Entry: 2.5 mg AM Step: ≥21 days

IX. Non-Pharmacologic Micro-Initiation

Compression garments Entry: 10–15 mmHg Step: ≥14 days

Activity expansion Entry: +3–5% baseline Step: ≥14 days

Light exposure therapy Entry: 5 minutes AM Step: ≥10 days

Cold exposure Entry: avoided in fragility

X. Environmental Gating Rules

No titration during:

• Smoke events 

• Storm fronts 

• Heat waves 

• Mold remediation 

• Travel weeks 

• Sleep collapse periods

Modeled as “pause zones.”

XI. Crash Phenotypes

Type A: Excitatory Crash

Agitation, insomnia, tachycardia → reduce dose 50–75%

Type B: Energy Collapse

Heavy fatigue, PEM → hold 14–21 days

Type C: Immune Rebound

Flu-like relapse → revert + delay immune layers

Type D: Autonomic Spiral

Syncope, BP instability → suspend titration

XII. Escalation Logic

Escalation only when:

• ≥10 stable days 

• No new crash pattern 

• Sleep ≥70% baseline 

• PEM amplitude reduced 

• Environmental load stable

Otherwise: hold.

XIII. Why This Layer Exists

Standard trials assume linear tolerance. IACCs violate that assumption. Micro-initiation encodes nonlinear entry physics.

These ranges reflect aggregated observational behavior and simulation constraints, not prescribing guidance. They exist to model failure modes and prevent destabilization in highly sensitive cohorts excluded from conventional trials.

Appendix B: Hormonal and Cycle-Aware Modeling Layer

Scope

In IACC patterns with autonomic, immune, or mast cell involvement, hormonal fluctuations are modeled as active modifiers of symptom volatility, treatment tolerance, and flare risk. This layer is applied when cyclic symptom variation, perimenopausal transition, or hormone therapy exposure is present.

Eligibility for Hormonal Layer Activation

This layer is engaged when ≥2 indicators are present:

• Symptoms worsen predictably every 3–5 weeks 

• Sleep collapses near menstrual cycles 

• PEM thresholds shift across the month 

• New medication intolerance appears cyclically 

• Flares cluster around bleeding or spotting 

• Perimenopausal instability reported

Cycle Phase Sensitivity Windows

Early Follicular (menstrual phase) High inflammatory and autonomic volatility Lowest tolerance for new interventions

Late Follicular / Ovulatory Transient energy increase High rebound risk

Mid-Luteal Increased fatigue and cognitive fog Lower mitochondrial reserve

Late Luteal / Premenstrual Highest mast cell and immune reactivity Highest flare probability

Perimenopause Loss of stable phase boundaries Prolonged volatility windows

Post-Menopause Reduced cyclicity Persistent low-reserve pattern

Hormone-Titration Interaction Rules

During high-risk phases:

• No new agents initiated 

• No dose escalation 

• No activity expansion 

• No tapering of stabilizers

Escalation is modeled only during lower-volatility windows.

Hormone-Linked Failure Patterns

Type H1: Premenstrual Amplification Sudden intolerance of stable doses

Type H2: Ovulatory Rebound Short energy surge → delayed crash

Type H3: Perimenopausal Drift Progressive loss of tolerance

Type H4: Exogenous Hormone Destabilization Flares following hormone therapy changes

Modeling Safeguards

When this layer is active:

• Observation windows extended by 25–40% 

• Stability thresholds raised 

• Environmental gating tightened 

• Immune titration slowed

This prevents misclassification of cyclical flares as treatment failure.

Research Implications

Failure to account for hormonal modulation leads to:

• False-negative trials 

• Overestimated side effects 

• Misattributed non-response 

• Exclusion of women from analysis

Cycle-aware modeling improves signal validity.

Androgen and HPA-Axis Modulation (All Sexes)

In some autonomic-dominant and post-viral patterns, fluctuations in testosterone and cortisol signaling interact with fatigue, blood volume, and immune reactivity.

Indicators include:

• Morning collapse patterns 

• Stress intolerance 

• Post-exertional hypotension 

• Sleep–energy uncoupling

When present, observation windows are extended and titration slowed. This prevents misattribution of endocrine-driven volatility.

Appendix C2: Natural Language Prompts With Minimum Viable Inputs and Common Data Sources

Scope

These examples show how everyday language, small data anchors, and existing personal records can be combined to support reliable IACC Twin™ modeling. Users are not expected to create new systems. Most required information already exists in daily life records.

1. “Did This Medication Ruin Me?”

Minimum Helpful Add-On

• Before vs after function

• Timing

• Sleep change

• Environment

• Recovery trend

Where This Data Usually Lives

• Patient portal visit summaries

• Email confirmations

• Medication lists

• Personal health apps

• Timeline notes

2. “Why Does the Weather Wreck Me?”

Minimum Helpful Add-On

• Symptoms

• Trigger type

• Frequency

• Indoor air notes

• Med stability

Where This Data Usually Lives

• Weather apps

• Air quality apps

• Smart home monitors

• Notes in phone

• Social posts (“air is killing me today”)

3. “ Why Can’t Tell If Anything Is Helping?”

Minimum Viable Inputs

• Current medication and supplement list

• Start dates and changes

• Observation window length

• Baseline symptom trend

• Overlapping interventions

• Recent environmental disruptions

Where This Data Usually Lives

• Pharmacy refill history

• Patient portal medication lists

• Calendar reminders

• Pill tracker apps

• Notes app

4. “Why Is It That Every Time I Do More, I Get Sicker?”

Minimum Viable Inputs

• Baseline activity level

• Typical activity increase size

• Delay before crash

• Crash duration

• Sleep changes after exertion

• Recovery time

Where This Data Usually Lives

• Step counters

• Fitness trackers

• Phone movement data

• Activity logs

• Social calendars

5. “Help Me Prove My Period Makes My Condition Flare"

Minimum Viable Inputs

• Cycle length and regularity

• Symptom peaks by phase

• Sleep disruption timing

• Medication tolerance changes

• Consistency across cycles

Where This Data Usually Lives

• Period tracking apps

• Health app cycle logs

• Calendar markings

• Journal entries

• Messages (“PMS flare”)

Social Media and Community Data (Optional)

Many patients already document symptom patterns publicly or semi-publicly.

Examples:

• Twitter/X threads

• Reddit posts

• Facebook group updates

• Substack blogs

• CaringBridge journals

• Medium essays

These often contain:

• timestamps

• trigger descriptions

• functional status

• emotional context

• relapse narratives

When used voluntarily and ethically, they can support longitudinal pattern reconstruction.

Design Principle: “Use What Already Exists”

IACC Twin™ is designed so that:

People do not need to become data scientists.

They do not need perfect logs.

They do not need special devices.

They can simply use their real life as data.

Evidence Reference Library and Citation Rotation Framework

This system is supported by an internal, curated Evidence Reference Library containing peer-reviewed research, cohort studies, and clinical reviews related to Long COVID, ME/CFS, dysautonomia, mast cell disorders, and infection-associated chronic conditions (IACCs).

References are organized into thematic evidence domains. When a pattern interpretation aligns with a domain, the system may draw from multiple anchor sources within that domain and rotate citations to avoid over-reliance on any single study.

Domain 1: Multisystem Symptom Burden and Functional Impact

This domain documents the breadth, severity, and daily-life consequences of post-viral illness.

Example anchors:

• Sawano M, Wu Y, Shah R, et al., Adinig C, Iwasaki A, Krumholz HM.

Long COVID Characteristics and Experience: Yale LISTEN Cohort. AJM, 2025.

• Davis HE et al.

Long COVID: Major Findings and Mechanisms. Nat Rev Microbiol, 2023.

• Ballering AV et al.

Persistence of Symptoms After COVID-19. JAMA, 2021.

Use when outputs discuss:

Widespread symptoms, quality of life, disability, employment loss, or social impact.

Domain 2: Post-Exertional Worsening and Energy Dysregulation (ME/CFS-Type Patterns)

This domain supports interpretations related to delayed crashes and activity intolerance.

Example anchors:

• Institute of Medicine.

Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. 2015.

• Davis HE et al.

Characterizing Long COVID in an International Cohort. EClinicalMedicine, 2021.

• Jason LA et al.

Post-Exertional Malaise in ME/CFS. J Health Psychol, 2018.

Use when outputs discuss:

Delayed crashes, pacing, recovery failure, or exertion sensitivity.

Domain 3: Autonomic Dysfunction and Orthostatic Intolerance

This domain supports cardiovascular and nervous system regulation patterns.

Example anchors:

• Raj SR et al.

Postural Orthostatic Tachycardia Syndrome. Circulation, 2013.

• Miglis MG et al.

Autonomic Dysfunction in Long COVID. Clin Auton Res, 2020.

• Dani M et al.

Autonomic Dysfunction After COVID-19. Heart Rhythm, 2021.

Use when outputs discuss:

Tachycardia, dizziness, blood pressure instability, syncope, temperature dysregulation.

Domain 4: Mast Cell Activation and Immune Reactivity

This domain supports allergic-type, inflammatory, and environmental sensitivity patterns.

Example anchors:

• Afrin LB et al.

Diagnosis of Mast Cell Activation Syndrome. J Hematol Oncol, 2017.

• Weinstock LB et al.

Mast Cell Activation in Long COVID. Int J Infect Dis, 2021.

• Theoharides TC et al.

Mast Cells and Neuroinflammation. J Neuroinflammation, 2020.

Use when outputs discuss:

Flushing, itching, food reactions, chemical sensitivity, histamine response.

Domain 5: Immune Dysregulation and Viral Persistence

This domain supports mechanistic and biomarker-level interpretations.

Example anchors:

• Iwasaki A et al.

Immune Profiling of Long COVID. Cell, 2023.

• Su Y et al.

Immune Signatures in Long COVID. Cell, 2022.

• Peluso MJ et al.

SARS-CoV-2 Antigen Persistence. Clin Infect Dis, 2021.

Use when outputs discuss:

Inflammation, immune exhaustion, viral reservoirs, cytokines.

Domain 6: Treatment Burden and Limited Therapeutic Efficacy

This domain supports discussion of polypharmacy and trial-and-error care.

Example anchors:

• Sawano M et al.

Yale LISTEN Treatment Patterns. AJM, 2025.

• Greenhalgh T et al.

Management of Post-Acute COVID. BMJ, 2020.

• Crook H et al.

Long COVID Mechanisms and Management. BMJ, 2021.

Use when outputs discuss:

Multiple failed treatments, high experimentation, lack of standards.

Domain 7: Psychosocial, Economic, and Structural Impact

This domain contextualizes distress without psychologizing disease.

Example anchors:

• Wright J et al.

Long COVID and Employment Impact. Lancet, 2022.

• Callard F, Perego E.

Social Dimensions of Long COVID. Soc Sci Med, 2021.

• Cutler DM.

Economic Cost of Long COVID. Brookings, 2022.

Use when outputs discuss:

Isolation, financial strain, work loss, stigma.

Citation Rotation Logic

When multiple domains apply, the system should:

• Select 1–2 relevant anchors per domain

• Rotate among available references across outputs

• Avoid repeating the same citation in consecutive responses

• Prefer more recent or higher-quality evidence when available

Example:

If discussing PEM + dysautonomia + mast cell features:

Pull from Domain 2 + 3 + 4

Rotate across at least two anchors per domain over time.

Evidence Use Governance

The reference library is used to:

• Support pattern recognition

• Validate symptom clusters

• Frame uncertainty

• Prevent oversimplification

It is not used to:

• Issue diagnoses

• Replace clinicians

• Provide prescriptive treatment plans

CYNAERA Frameworks Referenced in This Paper 

This paper draws on a defined subset of CYNAERA white papers that establish the theoretical, methodological, and operational foundations for Minimum Viable Data, phenotype mapping, remission mechanics, and volatility-aware sequencing in infection-associated chronic conditions (IACCs). The references below represent the minimum set required to interpret the models, definitions, and outcomes presented here.

Foundational theory and system behavior

https://www.cynaera.com/post/unified-theory

https://www.cynaera.com/post/pathophysiology-of-iacc

https://www.cynaera.com/post/iacc-terrain

https://www.cynaera.com/post/the-science-of-iacc-remission

https://www.cynaera.com/post/signal-noise

Minimum Viable Data, pattern mapping, and phenotype logic

https://www.cynaera.com/post/iacc-gpt

https://www.cynaera.com/post/patient-stratificationhttps://www.cynaera.com/post/mecfs-phenotypinghttps://www.cynaera.com/post/composite-diagnostic-fingerprint-for-lchttps://www.cynaera.com/post/pem-index

Remission sequencing and trial interpretation

https://www.cynaera.com/post/mecfs-remissionhttps://www.cynaera.com/post/mecfs-clinical-trialshttps://www.cynaera.com/post/mecfs-trial-fails

Environmental volatility and flare risk

https://www.cynaera.com/post/cynaera-s-vitalguard-environmental-flare-risk-enginehttps://www.cynaera.com/post/mecfs-environment

Prevalence correction and surveillance framing

https://www.cynaera.com/post/iacc-prevalence-us

Mechanism-based substitution and repurposing logic

https://www.cynaera.com/post/cynaera-repurposed

GPTs Referenced

https://chatgpt.com/g/g-1FMficYx5-neurosearching-by-cynaera

https://chatgpt.com/g/g-683e05d1b7588191b15e68e6e60f216f-iacc-clinical-trials-simulator

About CYNAERA Internal Clinical Trial Simulator

The CYNAERA Clinical Trial Simulator is designed to prevent baseline loss before it happens. It is the first terrain-based modeling system that merges immunology, autonomic stability, and environmental data into one decision intelligence platform.

Built from more than two hundred million synthetic patient journeys, the simulator reconstructs every stage of a clinical trial. It predicts efficacy, safety, dropout rates, and equity impact before recruitment even begins. For universities, hospitals, and early-stage biotech companies, this means less wasted time, lower cost per protocol, and more confidence when moving from concept to patient outcome.

The CYNAERA Clinical Trial Simulator is built to operate across most disease categories that involve immune, metabolic, or environmental interaction. The engine does not rely on a single diagnostic code or biomarker but instead interprets the body’s terrain as a living network of immune, vascular, and neurological feedback loops. This approach allows the simulator to work across hundreds of research domains while maintaining accuracy at population, biomarker, and outcome levels. It can accurately work across multiple condition, but it was built to assist: Long COVID, ME/CFS, Chronic Lyme, Mast Cell Activation Syndrome, Postural Orthostatic Tachycardia Syndrome, and related post-viral syndromes.

High accuracy analysis also includes:

• Neuroimmune and Autonomic Disorders: Fibromyalgia, CRPS, small fiber neuropathy, autonomic instability, and dysautonomia-driven inflammatory states.

• Hormone–Immune Axis Conditions: Menopause-related immune rebound, PCOS inflammatory phenotypes, testosterone and estrogen immune modulation studies.

• Oncology and Immune Collapse Pathways: Conditions modeled under CRATE™ for tumor microenvironment instability, cytokine persistence, and pre-cancer terrain prediction.

• Environmental and Climate-Linked Illnesses: Mold-related disease, wildfire smoke sensitivity, air pollution–induced autonomic flare risk, and water contamination studies through VitalGuard™ overlays.

Learn More: Clinical Trial Simulator

Author’s Note:

All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.

Patent-Pending Systems

​Bioadaptive Systems Therapeutics™ (BST) and all affiliated CYNAERA frameworks, including Pathos™, VitalGuard™, CRATE™, SymCas™, TrialSim™, and BRAGS™, are protected under U.S. Provisional Patent Application No. 63/909,951.

Licensing and Integration

CYNAERA partners with universities, research teams, federal agencies, health systems, technology companies, and philanthropic organizations. Partners can license individual modules, full suites, or enterprise architecture. Integration pathways include research co-development, diagnostic modernization projects, climate-linked health forecasting, and trial stabilization for complex cohorts. You can get basic licensing here at CYNAERA Market.

Support structures are available for partners who want hands-on implementation, long-term maintenance, or limited-scope pilot programs.

About the Author 

Cynthia Adinig is a researcher, health policy advisor, author, and patient advocate. She is the founder of CYNAERA and creator of the patent-pending Bioadaptive Systems Therapeutics (BST)™ platform. She serves as a PCORI Merit Reviewer, Board Member at Solve M.E., and collaborator with Selin Lab for t cell research at the University of Massachusetts.

Cynthia has co-authored research with Harlan Krumholz, MD, Dr. Akiko Iwasaki, and Dr. David Putrino, though Yale’s LISTEN Study, advised Amy Proal, PhD’s research group at Mount Sinai through its patient advisory board, and worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. She has also authored a Milken Institute essay on AI and healthcare, testified before Congress, and worked with congressional offices on multiple legislative initiatives. Cynthia has led national advocacy teams on Capitol Hill and continues to advise on chronic-illness policy and data-modernization efforts.

Through CYNAERA, she develops modular AI platforms, including the IACC Progression Continuum™, Primary Chronic Trigger (PCT)™, RAVYNS™, and US-CCUC™, that are made to help governments, universities, and clinical teams model infection-associated conditions and improve precision in research and trial design. US-CCUC™ prevalence correction estimates have been used by patient advocates in congressional discussions related to IACC research funding and policy priorities. Cynthia has been featured in TIME, Bloomberg, USA Today, and other major outlets, for community engagement, policy and reflecting her ongoing commitment to advancing innovation and resilience from her home in Northern Virginia.

Cynthia’s work with complex chronic conditions is deeply informed by her lived experience surviving the first wave of the pandemic, which strengthened her dedication to reforming how chronic conditions are understood, studied, and treated. She is also an advocate for domestic-violence prevention and patient safety, bringing a trauma-informed perspective to her research and policy initiatives.